Effect of Anti–LAF-1-Antibodies on Blood Cell Counts
| . | Treatment-150 . | ||||||
|---|---|---|---|---|---|---|---|
| PBS/IL-8 . | Anti–LAF-1/PBS . | Anti–LAF-1/IL-8 . | Anti–VLA-4/IL-8 . | Anti–ICAM-1/IL-8 . | PBS/IL-1 . | Anti–LAF-1/IL-1 . | |
| RBCs (×1012/L) | 8.2 ± 0.7 | 8.9 ± 0.6 | 8.7 ± 0.8 | 8.1 ± 0.3 | 7.7 ± 0.8 | 7.2 ± 0.2 | 7.2 ± 0.3 |
| WBCs (×109/L) | 7.9 ± 1.5 | 9.8 ± 1.7 | 6.7 ± 1.9 | 8.3 ± 1.9 | 7.4 ± 1.7 | 7.2 ± 1.2 | 5.1 ± 0.8 |
| Neutrophils (%) | 16.6 ± 5.5 | 13.8 ± 4.6 | 17.7 ± 9.7 | ND | 11 ± 7.5 | 53 ± 3.5 | 49 ± 8.0 |
| Plts (×109/L) | 739 ± 109 | 290 ± 36-151 | 312 ± 60-151 | 634 ± 100 | 682 ± 87 | 599 ± 47 | 235 ± 44-151 |
| . | Treatment-150 . | ||||||
|---|---|---|---|---|---|---|---|
| PBS/IL-8 . | Anti–LAF-1/PBS . | Anti–LAF-1/IL-8 . | Anti–VLA-4/IL-8 . | Anti–ICAM-1/IL-8 . | PBS/IL-1 . | Anti–LAF-1/IL-1 . | |
| RBCs (×1012/L) | 8.2 ± 0.7 | 8.9 ± 0.6 | 8.7 ± 0.8 | 8.1 ± 0.3 | 7.7 ± 0.8 | 7.2 ± 0.2 | 7.2 ± 0.3 |
| WBCs (×109/L) | 7.9 ± 1.5 | 9.8 ± 1.7 | 6.7 ± 1.9 | 8.3 ± 1.9 | 7.4 ± 1.7 | 7.2 ± 1.2 | 5.1 ± 0.8 |
| Neutrophils (%) | 16.6 ± 5.5 | 13.8 ± 4.6 | 17.7 ± 9.7 | ND | 11 ± 7.5 | 53 ± 3.5 | 49 ± 8.0 |
| Plts (×109/L) | 739 ± 109 | 290 ± 36-151 | 312 ± 60-151 | 634 ± 100 | 682 ± 87 | 599 ± 47 | 235 ± 44-151 |
Abbreviation: ND, not done.
Mice were treated with a single IP injection of 100 μg anti–LFA-1 (H154.163), 300 μg anti–VLA-4 (R1-2), 300 μg anti–ICAM-1 (YN1/1.7) or saline (PBS) at day −1. At day 0, 30 μg of IL-8, 1 μg of IL-1 or PBS was administered IP. Blood was obtained by cardiac puncture at 20 minutes after IL-8 and at 5 hours after IL-1 injection. Results are expressed as mean ± SD (n = 20 for saline/IL-8 and anti–LFA-1/IL-8, n = 4 for anti–LFA-1/saline, n = 10 for anti–VLA-4/IL-8, n = 8 for anti–ICAM-1/IL-8, and n = 6 for saline/IL-1 and anti–LFA-1/IL-1).
P < .001.